Surge Protector: Novel Approach to Suppressing Therapy-Induced Tumor Growth
Jacqueline Mitchell (BIDMC Communications) 617-667-7306, email@example.com
JANUARY 09, 2019
BIDMC Research Briefs showcase groundbreaking scientific advances that are transforming medical care.
In a recent groundbreaking study, a team of researchers led by BIDMC’s Dipak Panigrahy, MD, demonstrated that dead and dying cancer cells killed by conventional cancer treatments paradoxically trigger the inflammation that promotes tumor growth and metastasis. Now, in a follow- up study published in January in Proceedings of the National Academy of Science (PNAS), Panigrahy and colleagues illuminate the mechanism by which debris generated by ovarian tumor cells targeted by first-line chemotherapy accelerates tumor progression. Additionally, the researchers describe a novel approach to suppressing the chemotherapy-induced tumor growth.
“Conventional cancer therapy is a double-edged sword – the very treatment meant to control cancer is also helping it to survive and grow,” said Panigrahy, Assistant Professor of Pathology in the Department of Pathology and a Scientist at the Cancer Center at BIDMC. “To prevent tumor recurrence after therapy, it will be critical to neutralize the inherent tumor-promoting activity of therapy-generated debris.”
Panigrahy and colleagues’ analysis revealed that chemotherapy-killed ovarian cancer cells induce surrounding immune cells called macrophages to release a surge of immune-related chemical compounds – cytokines and lipid mediators – that create optimal conditions in which tumors can survive and grow. Next, the team showed that a common anti-inflammatory drug called a dual COX-2 inhibitor to block that surge of tumor-friendly cytokines and lipids.
“The role of these chemotherapy-induced cytokines and lipids is underappreciated and poorly characterized, and ovarian cancer patients may benefit from suppressing their release,” said Panigrahy. “Further research is needed but, dual inhibition of the COX-2 pathways is a novel therapeutic modality that may compliment conventional cancer therapies by acting as a surge protector against cell debris-stimulated tumor growth.”
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.